VKVaishali A. Kilor

Vaishali A. Kilor

*This is an algorithmically generated author record based on publicly available information.

Vaishali A. Kilor has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Review of clinical studies of herbal products as a treatment option in recurrent Aphthous stomatitis

    by Vaishali Kilor, Nidhi Sapkal, Sana Shaikh

    Recurrent aphthous stomatitis (RAS) is the repeated occurrence of lesions in the intraoral sites having diverse etiology leading to pain, inflammation, and difficulty in eating and speaking. Common treatment options available for RAS are analgesics, corticosteroids, local anesthetics, and antimicrobial agents. The purpose is to reduce the intensity of pain, inflammation, and duration of the ulcer. All the above-mentioned medications if used for a longer duration may result in several complications including antibiotic resistance. It is commonly observed that patients suffering from RAS initiate self-treatment like the application of honey, and turmeric to ulcers, chewing of guava leaves, beetle leaves, etc., based on traditional knowledge which results in inconsistent relief and ultimately treatment shifts towards the use of corticosteroids, analgesic as well as antibiotics. There is a need for evidence-based systematic studies that lead to the availability of formulations containing herbal medicines for guaranteed quick relief from pain and reducing recurrence of mouth ulcers. Thus, to prove efficacy of traditional herbal medicine, several clinical trials are being done where these medicines are used as single extract for topical application. The present study aims to critically assess the available data of clinical trials on the topical treatment of RAS using plant-based medicines and identify the most promising plant-based medicine that gives quick relief from RAS.


  • Open Access

    DEVELOPMENT OF STABLE NANOSUSPENSION LOADED ORAL FILMS OF GLIMEPIRIDE WITH IMPROVED BIOAVAILABILITY

    by Vaishali Kilor, Nidhi Sapkal, Anwar Daud, Shruti Humne, Tushar Gupta

    Objective: In the present work attempt has been made to stabilize optimized nanosuspensions of glimepiride by solidification using a novel Oral Thin Film (OTF) formulation.Methods: Nanosuspensions were characterized for particle size, zeta potential as well as in vitro dissolution profile. As nanosuspensions are prone to destabilization by Ostwald’s ripening or agglomeration/aggregation, OTF formulation as a novel approach for stabilization through solidification of optimized nanosuspension was attempted. OTF formulation method is a simple, easy and scalable method for the preparation of solid oral dosage form. Prepared formulations were evaluated for physicochemical parameters like folding endurance, disintegration time, tensile strength, in vitro drug release, in vivo bioavailability and stability.Results: The mean particle size of the nanoparticles in OTF was found to be 57.2 nm. It was observed from the results of in vivo bioavailability studies that high plasma drug concentrations(Cmax) were achieved for nanosuspension loaded OTF (NSOTF) i.e. 4900 ng/ml as compared to marketed oral formulation (Cmax-2900 ng/ml). Results of the stability studies indicated that nanosize of the particles was retained even after 3 mo of the study.Conclusion: Therefore it can be concluded that OTF formulation has a potential for stabilization of nanosuspensions.


  • Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using κ-Carrageenan as a Pelletizing Agent

    by Vaishali A. Kilor, Nidhi P. Sapkal, Jasmine G. Awari, Bharti D. Shewale

    In the present study, an attempt was made to prepare immediate-release enteric-coated pellets of aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a gastrointestinal intolerance as its serious side effect. Formulation of enteric-coated pellets with improved solubility of aceclofenac could address both of these problems. To achieve these goals, pellets were prepared by extrusion–spheronization method using pelletizing agents that can contribute to the faster disintegration and thereby improve the solubility of the drug. Different disintegrants like β-cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in order to further improve disintegration time. The pellets were characterized for drug content, particle size distribution, flow properties, infrared spectroscopy, surface morphology, disintegration rate, and dissolution profile. The formulations, which showed best disintegration and dissolution profiles, were coated with Eudragit L100-55, an enteric-coated polymer which does not dissolve at gastric pH but dissolves at intestinal pH, releasing the drug immediately in the dissolution medium. The optimized enteric-coated formulation containing 20% κ-carrageenan, lactose, and sodium starch glycolate as a disintegrant did inhibit the release of the drug for 2 h in 0.1 N HCl, whereas 87% of the drug was released within 45 min. The improvement was substantial when it was compared with solubility of pure drug under the same conditions. Thus, dissolution profiles suggested that combination of κ-carrageenan and sodium starch glycolate resulted into fast-disintegrating, immediate-release pellets, overcoming the bioavailability problem of the poorly soluble drug, aceclofenac, and enteric coating of these pellets avoids the exposure of aceclofenac to ulcer-prone areas of the gastrointestinal tract.